Chemotherapy-Related Toxicities In Ovarian Cancer Patients
To assess the preferences of women with ovarian cancer, their clinical caregivers, familial caregivers, and a control group for toxicities associated with chemotherapy.
- To compare preferences of women with ovarian cancer to preferences of their clinical caregivers.
- To compare preferences of women with ovarian cancer to preferences of their familial caregivers.
- To compare preferences of women with ovarian cancer to preferences of a women in the control group.
- To prospectively collect quality of life data from women with ovarian cancer.
- To prospectively collect symptom assessment data from women with ovarian cancer.
|Study Design:||Observational Model: Case-Only
Time Perspective: Prospective
|Official Title:||Chemotherapy-Related Toxicities In Ovarian Cancer Patients: Preference Assessments of Patients, Family Members, Ancillary Staff and Gynecologic Oncologists, and Patients' Quality of Life|
- Qualitative information on how ovarian cancer patients, their family members, and doctors and nurses feel about the side-effects of chemotherapy. [ Time Frame: 8 Years ] [ Designated as safety issue: No ]
- Patient Response to Quality of Life Using Interview + Questionnaire [ Time Frame: 30 minute interviews + 15 minutes for questionnaire ] [ Designated as safety issue: No ]
|Study Start Date:||January 2001|
|Estimated Primary Completion Date:||January 2015 (Final data collection date for primary outcome measure)|
|Interview & Questionnaires||
Interview regarding side-effects of chemotherapy, 30-45 minutes.
Other Name: SurveyBehavioral: Questionnaire
Quality of life survey and symptom assessment questionnaire, 15 minutes.
Patients in this study will be recruited from the Gynecologic Oncology Clinic waiting area. All participants (patients, family and clinical caregivers, control group women with no cancer) in this study will take part in an interview to see how they feel about the different side-effects of chemotherapy. The interview will involve reading short descriptions of the side-effects and then answering some questions that ask for an opinion. The actual interview will take about 30-45 minutes to complete. The interviews will either take place in private conference rooms in the clinic or in private rooms at the Ambulatory Treatment Center (ATC).
Patients will also be given quality of life and symptom assessment questionnaires. The questionnaires are simple to read and quick to answer. The questionnaire takes about 15 minutes to complete.
The participant's involvement in this study is limited to the questionnaire/interview. Once that is done, the participant is finished with the study.
This is an investigational study. A total of 288 people will take part in this study. All will be enrolled at M. D. Anderson.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00508378
|United States, Texas|
|UT MD Anderson Cancer Center|
|Houston, Texas, United States, 77030|
|Principal Investigator:||Diane C. Bodurka, MD||M.D. Anderson Cancer Center|